THU-175-Eligibility and feasibility of hepatitis C treatment in the era of direct-acting antiviral agents: Our experience in real-world practice
Monica Schiavini(ASST Fatebenefratelli Sacco), Giuliano Rizzardini, Simona Landonio(ASST Fatebenefratelli Sacco), Stefania Vimercati(Qinetiq (United Kingdom)), Annalisa Mainini(Luigi Sacco Hospital), G. Gubertini, Riccardo De Giorgi(Warneford Hospital), Simone Passerini(Office of Infectious Diseases), Elena Angeli(Luigi Sacco Hospital), Matteo Passerini(University of Milan), C. Magni(ASST Fatebenefratelli Sacco), Alessandro Luciano Croci(Office of Infectious Diseases), Fosca Niero(Luigi Sacco Hospital), Matteo Bolis(Ospedale Amedeo di Savoia)
Cited by 0
Related Papers
Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection
|New England Journal of Medicine|2022|264
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C
|Journal of Hepatology|2018|133
Incidence of Adverse Reactions in HIV Patients Treated With Protease Inhibitors: A Cohort Study
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2000|115
Incidence of Adverse Reactions in HIV Patients Treated With Protease Inhibitors: A Cohort Study
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2000|97